1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents – A Review

ACS Pharmacology & Translational Science, Год журнала: 2024, Номер 7(6), С. 1722 - 1745

Опубликована: Май 8, 2024

1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI, or DOX where X = −I) was first synthesized in 1973 a structure–activity study to explore the effect of various aryl substituents on then newly identified, and subsequently controlled, hallucinogenic agent 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM, −CH3). Over time, DOI found be serotonin (5-HT) receptor agonist using peripheral 5-HT tissue assays later, following identification multiple families central receptors, an at 5-HT2 receptors rat and, then, human brain. Today, classical hallucinogens, currently referred as serotonergic psychedelic agents, are receiving considerable attention for their potential therapeutic application neuropsychiatric disorders including treatment-resistant depression. Here, we review, historical current developments that led becoming unique, perhaps landmark, research.

Язык: Английский

---

Cardiac effects of two hallucinogenic natural products, N,N-dimethyl-tryptamine and 5-methoxy-N,N-dimethyl-tryptamine

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Фев. 25, 2025

Язык: Английский

---

Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases

Cochrane library, Год журнала: 2024, Номер 2024(9)

Опубликована: Сен. 12, 2024

Язык: Английский

---

Psychedelics in neuroinflammation: Mechanisms and therapeutic potential

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2025, Номер unknown, С. 111278 - 111278

Опубликована: Янв. 1, 2025

Язык: Английский

---

Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study

Journal of Psychopharmacology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 28, 2025

Background: Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects of single dose have not been investigated. Aims: To investigate pharmacokinetics, feasibility, safety and efficacy single-dose psilocybin therapy in AUD. Methods: This open-label, single-group study investigated 10 treatment-seeking adults (8 men 2 women; median age 44 years) severe The involved preparation high-dose session (25 mg) integration sessions. Pharmacokinetics were determined by noncompartmental analysis, changes consumption, craving self-efficacy, assessed using linear mixed model. Results: Notable between-participant pharmacokinetic variations observed, peak plasma psilocin concentrations ranging from 14 to 59 µg/L. Alcohol consumption significantly decreased over 12 weeks following administration. Heavy drinking days reduced 37.5 percentage points (95% CI: −61.1 −13.9, p = 0.005), drinks per day 3.4 −6.5 −0.3, 0.03). was corroborated reports rapid sustained reductions increases self-efficacy. Conclusions: Despite variations, 25 mg safe effective reducing AUD patients. Larger randomised, placebo-controlled, trials are warranted. Clinical trial registration: https://clinicaltrials.gov/study/NCT04718792

Язык: Английский

---

Treatment-emergent symptoms during short-term ketamine administration in treatment-resistant bipolar depression: a retrospective cross-sectional descriptive study

Asian Journal of Psychiatry, Год журнала: 2024, Номер 99, С. 104159 - 104159

Опубликована: Июль 15, 2024

Язык: Английский

---

Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials

Frontiers in Psychiatry, Год журнала: 2024, Номер 15

Опубликована: Сен. 19, 2024

Introduction Psychedelic agents have regained the attention of pharmaceutical companies as promising treatments for depressive episodes. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), an atypical psychedelic, is emerging a potentially effective, novel rapid-acting antidepressant. In this systematic review, we analyze safety and tolerability evidence from clinical trials. Methods Following Preferred Reporting Items Systematic Reviews Meta-analyses (PRISMA) guidelines, electronic databases (PubMed, SCOPUS, Web Science, EMBASE, EBSCO) were searched inception until 15 May 2024 to identify trials (regardless phase) reporting on short-term profile 5-MeO-DMT using following keywords in various combinations: 5-methoxy-N, N-dimethyltryptamine, 5-MeO-DMT, safety, adverse, adverse reaction, side effects, tolerability, dropout, healthy volunteer, participant, depression, major disorder. Only studies written English considered. Results Initial search yielded 100 records, out which 3 met inclusion criteria. These reported results trial phases I I/II, with total 78 participants included; two involved volunteers, one included patients treatment-resistant depression. Although data limited, it confirms good no serious events (SAEs) reported. Furthermore, drop-outs Conclusion administration human subjects presents favorable profile. Importantly, SAEs been documented, led participant withdrawal There need future randomized, double-blind, placebo-controlled larger samples follow-up assess potential chronic events.

Язык: Английский

---

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response

Journal of Psychopharmacology, Год журнала: 2024, Номер 38(10), С. 873 - 886

Опубликована: Сен. 20, 2024

Psychedelic-assisted therapy (PAT) is permitted in Switzerland under its limited medical use program. Data from patients this program represent a unique opportunity to analyze the real-world practice of PAT.

Язык: Английский

---

A Comprehensive Review of the Diversity of Fungal Secondary Metabolites and Their Emerging Applications in Healthcare and Environment

Mycobiology, Год журнала: 2024, Номер 52(6), С. 335 - 387

Опубликована: Ноя. 1, 2024

Fungi and their natural products, like secondary metabolites, have gained a huge demand in the last decade due to increasing applications healthcare, environmental cleanup, biotechnology-based industries. The fungi produce these metabolites (SMs) during different phases of growth, which are categorized into terpenoids, alkaloids, polyketides, non-ribosomal peptides. These SMs exhibit significant biological activity, contributes formulation novel pharmaceuticals, biopesticides, bioremediation agents. Nowadays, fungal-derived widely used food beverages, for fermentation, preservatives, protein sources, dairy In it is being as an antimicrobial, anticancer, anti-inflammatory, immunosuppressive drug. usage modern tools biotechnology can achieve increase large-scale production. present review comprehensively analyses diversity fungal along with emerging agriculture, sustainability, nutraceuticals. Here, authors reviewed recent advancements genetic engineering, metabolic pathway manipulation, synthetic biology improve production yield SMs. Advancement fermentation techniques, bioprocessing, co-cultivation approaches Investigators further highlighted importance omics technologies understanding regulation biosynthesis SMs, offers drug discovery sustainable agriculture. Finally, addressed potential manipulation biotechnological innovations exploitation commercial benefits.

Язык: Английский

---

Psychedelika in der Psychiatrie

Nervenheilkunde, Год журнала: 2024, Номер 43(05), С. 236 - 241

Опубликована: Апрель 1, 2024

ZUSAMMENFASSUNG Psychedelika stoßen in der Psychiatrie auf ein erneut zunehmendes fachliches und wissenschaftliches Interesse. Nach einer intensiveren Phase des Einsatzes im psychotherapeutischen Kontext Mitte letzten Jahrhunderts kam die Forschung dem Bereich nach gesetzlichen Verboten weitestgehend zum Erliegen. Erst seit wenigen Jahren wird das klinische Potenzial wieder mit modernen wissenschaftlichen Methoden erforscht. Die Eigenschaft Psychedelika, qualitativ veränderte Bewusstseinszustände auch psychodynamischen Erfahrungen Erkenntnissen hervorzurufen, legt Möglichkeit nahe, sie zur Unterstützung von Prozessen zu nutzen. Bisherige Indikationsgebiete klinischen Studien betreffen vor allem den Einsatz bei therapieresistenten Depressionen, aber posttraumatischen Belastungsstörungen Alkoholabhängigkeit. Allerdings muss festgehalten werden, dass eine spezifische Psychedelika-Psychotherapie engeren Sinnen noch nicht erforscht wird. Neben Ausbau Evidenzlage ist diesem Feld einiges einem eventuellen breiteren erarbeiten.

---